Fate Therapeutics (FATE) Competitors $1.73 -0.03 (-1.42%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$1.75 +0.02 (+1.39%) As of 06:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FATE vs. DBVT, EVO, SEPN, SVRA, and CVACShould you buy Fate Therapeutics stock or one of its competitors? MarketBeat compares Fate Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fate Therapeutics include DBV Technologies (DBVT), Evotec (EVO), Septerna (SEPN), Savara (SVRA), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry. FATE vs. DBVTFATE vs. EVOFATE vs. SEPNFATE vs. SVRAFATE vs. CVACHow does Fate Therapeutics compare to DBV Technologies?DBV Technologies (NASDAQ:DBVT) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk. Is DBVT or FATE more profitable? Fate Therapeutics has a net margin of -2,056.79% compared to DBV Technologies' net margin of -2,895.37%. Fate Therapeutics' return on equity of -58.89% beat DBV Technologies' return on equity.Company Net Margins Return on Equity Return on Assets DBV Technologies-2,895.37% -129.88% -88.84% Fate Therapeutics -2,056.79%-58.89%-39.39% Do analysts prefer DBVT or FATE? DBV Technologies currently has a consensus target price of $40.25, suggesting a potential upside of 114.67%. Fate Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 217.92%. Given Fate Therapeutics' higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than DBV Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DBV Technologies 2 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.67Fate Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Does the media refer more to DBVT or FATE? In the previous week, DBV Technologies and DBV Technologies both had 4 articles in the media. Fate Therapeutics' average media sentiment score of 0.49 beat DBV Technologies' score of 0.37 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, DBVT or FATE? DBV Technologies has a beta of -0.96, indicating that its stock price is 196% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.13, indicating that its stock price is 113% more volatile than the broader market. Do institutionals & insiders hold more shares of DBVT or FATE? 71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, DBVT or FATE? Fate Therapeutics has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDBV Technologies$5.64M196.84-$146.95M-$4.46N/AFate Therapeutics$6.65M30.32-$136.32M-$1.09N/A SummaryFate Therapeutics beats DBV Technologies on 12 of the 16 factors compared between the two stocks.How does Fate Therapeutics compare to Evotec?Fate Therapeutics (NASDAQ:FATE) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment. Which has preferable valuation & earnings, FATE or EVO? Evotec has higher revenue and earnings than Fate Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$6.65M30.32-$136.32M-$1.09N/AEvotec$891.97M1.09-$117.12MN/AN/A Do analysts recommend FATE or EVO? Fate Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 217.92%. Evotec has a consensus target price of $7.00, suggesting a potential upside of 155.47%. Given Fate Therapeutics' higher probable upside, equities analysts plainly believe Fate Therapeutics is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Evotec 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is FATE or EVO more profitable? Evotec has a net margin of -26.20% compared to Fate Therapeutics' net margin of -2,056.79%. Evotec's return on equity of -24.93% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-2,056.79% -58.89% -39.39% Evotec -26.20%-24.93%-11.35% Which has more risk & volatility, FATE or EVO? Fate Therapeutics has a beta of 2.13, meaning that its share price is 113% more volatile than the broader market. Comparatively, Evotec has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market. Do insiders and institutionals believe in FATE or EVO? 97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer FATE or EVO? In the previous week, Fate Therapeutics had 2 more articles in the media than Evotec. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for Evotec. Evotec's average media sentiment score of 0.56 beat Fate Therapeutics' score of 0.49 indicating that Evotec is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evotec 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryEvotec beats Fate Therapeutics on 8 of the 14 factors compared between the two stocks.How does Fate Therapeutics compare to Septerna?Fate Therapeutics (NASDAQ:FATE) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends. Is FATE or SEPN more profitable? Septerna has a net margin of -49.88% compared to Fate Therapeutics' net margin of -2,056.79%. Septerna's return on equity of -12.72% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-2,056.79% -58.89% -39.39% Septerna -49.88%-12.72%-8.87% Does the media refer more to FATE or SEPN? In the previous week, Septerna had 12 more articles in the media than Fate Therapeutics. MarketBeat recorded 16 mentions for Septerna and 4 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 0.49 beat Septerna's score of -0.06 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Septerna 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals hold more shares of FATE or SEPN? 97.5% of Fate Therapeutics shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Septerna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts recommend FATE or SEPN? Fate Therapeutics currently has a consensus price target of $5.50, suggesting a potential upside of 217.92%. Septerna has a consensus price target of $43.13, suggesting a potential upside of 63.97%. Given Fate Therapeutics' higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than Septerna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Septerna 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has more volatility & risk, FATE or SEPN? Fate Therapeutics has a beta of 2.13, suggesting that its stock price is 113% more volatile than the broader market. Comparatively, Septerna has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market. Which has higher valuation & earnings, FATE or SEPN? Septerna has higher revenue and earnings than Fate Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$6.65M30.32-$136.32M-$1.09N/ASepterna$45.95M25.80-$48.88M-$0.81N/A SummarySepterna beats Fate Therapeutics on 11 of the 17 factors compared between the two stocks.How does Fate Therapeutics compare to Savara?Fate Therapeutics (NASDAQ:FATE) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Is FATE or SVRA more profitable? Savara has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Fate Therapeutics' return on equity of -58.89% beat Savara's return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-2,056.79% -58.89% -39.39% Savara N/A -87.19%-66.42% Which has more volatility and risk, FATE or SVRA? Fate Therapeutics has a beta of 2.13, suggesting that its share price is 113% more volatile than the broader market. Comparatively, Savara has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Does the media refer more to FATE or SVRA? In the previous week, Savara had 14 more articles in the media than Fate Therapeutics. MarketBeat recorded 18 mentions for Savara and 4 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 0.49 beat Savara's score of -0.47 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Savara 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend FATE or SVRA? Fate Therapeutics presently has a consensus target price of $5.50, suggesting a potential upside of 217.92%. Savara has a consensus target price of $9.13, suggesting a potential upside of 85.85%. Given Fate Therapeutics' higher possible upside, equities analysts plainly believe Fate Therapeutics is more favorable than Savara.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Savara 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Which has preferable valuation and earnings, FATE or SVRA? Savara has lower revenue, but higher earnings than Fate Therapeutics. Savara is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$6.65M30.32-$136.32M-$1.09N/ASavaraN/AN/A-$118.84M-$0.56N/A Do institutionals and insiders hold more shares of FATE or SVRA? 97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryFate Therapeutics and Savara tied by winning 8 of the 16 factors compared between the two stocks.How does Fate Therapeutics compare to CureVac?Fate Therapeutics (NASDAQ:FATE) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations. Which has stronger earnings & valuation, FATE or CVAC? CureVac has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$6.65M30.32-$136.32M-$1.09N/ACureVac$70.74M14.78$175.50M$0.726.47 Which has more risk & volatility, FATE or CVAC? Fate Therapeutics has a beta of 2.13, suggesting that its stock price is 113% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Do analysts recommend FATE or CVAC? Fate Therapeutics currently has a consensus price target of $5.50, suggesting a potential upside of 217.92%. CureVac has a consensus price target of $6.83, suggesting a potential upside of 46.64%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Fate Therapeutics is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17CureVac 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 Do institutionals & insiders hold more shares of FATE or CVAC? 97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is FATE or CVAC more profitable? CureVac has a net margin of 199.92% compared to Fate Therapeutics' net margin of -2,056.79%. CureVac's return on equity of -23.03% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-2,056.79% -58.89% -39.39% CureVac 199.92%-23.03%-19.09% Does the media refer more to FATE or CVAC? In the previous week, Fate Therapeutics had 4 more articles in the media than CureVac. MarketBeat recorded 4 mentions for Fate Therapeutics and 0 mentions for CureVac. Fate Therapeutics' average media sentiment score of 0.49 beat CureVac's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Fate Therapeutics Neutral CureVac Neutral SummaryFate Therapeutics beats CureVac on 9 of the 16 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition ExportMetricFate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$204.56M$3.31B$6.25B$12.29BDividend YieldN/A2.34%2.80%5.32%P/E Ratio-1.5918.1320.6425.23Price / Sales30.32289.87554.8579.36Price / CashN/A55.2727.4837.30Price / Book0.966.579.666.63Net Income-$136.32M$24.35M$3.56B$335.59M7 Day Performance-23.11%-2.53%-1.65%-1.20%1 Month Performance24.46%-3.55%-2.60%-1.16%1 Year Performance41.80%53.51%30.07%28.10% Fate Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics2.9438 of 5 stars$1.73-1.4%$5.50+217.9%+61.7%$204.56M$6.65MN/A550Earnings ReportDBVTDBV Technologies2.909 of 5 stars$20.36+3.2%$40.25+97.7%+68.9%$1.10B$5.64MN/A80EVOEvotec3.0199 of 5 stars$3.06-0.3%$7.00+128.8%-32.5%$1.09B$891.97MN/A4,553SEPNSepterna3.151 of 5 stars$23.57-1.3%$43.13+83.0%+167.3%$1.07B$45.95MN/AN/AEarnings ReportUpcoming EarningsSVRASavara2.3493 of 5 stars$5.12-2.1%$9.13+78.2%+59.9%$1.07BN/AN/A20Earnings Report Related Companies and Tools Related Companies DBV Technologies Alternatives Evotec Alternatives Septerna Alternatives Savara Alternatives CureVac Alternatives Aktis Oncology Alternatives Alvotech Alternatives Phathom Pharmaceuticals Alternatives Schrodinger Alternatives Cronos Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
